With yet another disappointment in the bag, maybe the Dendreon (DNDN)
bulls can take a break with the "success is just around the corner"
stories. Every controversial story has its supporters, but supporting
Dendreon has come at a high cost as the price has continued to break
down on successive disappointments with the cancer vaccine Provenge.
I
hope that with second quarter results in hand and a significant
restructuring on the way, the argument will at last shift from whether
Provenge is a great drug (it's not) to whether it's a salvageable
business (it might be).
Please read more here:
DONE-Dreon?
No comments:
Post a Comment